Offering of 4.5 million shares has greenshoe for 675,000 more
By Jennifer Chiou
New York, May 10 - Complete Genomics, Inc. priced a $64.64 million public sale of stock with a $9.7 million over-allotment option for 675,000 additional shares, according to an S-1 filing with the Securities and Exchange Commission.
The company will sell 4.5 million common shares at a proposed maximum offering price of $14.365 apiece. The price per share is a 2.83% discount to the May 6 closing share price of $14.78.
Jefferies & Co., Inc. and UBS Investment Bank are the leads for the deal with Robert W. Baird & Co. Inc. and Cowen and Co., LLC as co-managers.
Anticipated net proceeds of about $62 million - or $71.4 million with a full greenshoe exercise -are slated for capital expenditures and general corporate purposes.
The Mountain View, Calif.-based life sciences company has developed and commercialized a deoxyribonucleic acid sequencing platform.
| Issuer: | Complete Genomics, Inc.
|
| Issue: | Common shares
|
| Amount: | $64,642,500
|
| Greenshoe: | $9,696,375
|
| Shares: | 4.5 million
|
| Price: | $14.365 (maximum)
|
| Warrants: | No
|
| Underwriters: | Jefferies & Co., Inc. and UBS Investment Bank (leads); Robert W. Baird & Co. Inc. and Cowen and Co., LLC (co-managers)
|
| Pricing date: | May 6
|
| Stock symbol: | Nasdaq: GNOM
|
| Stock price: | $14.02 at close May 9
|
| Market capitalization: | $399.78 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
